Graham Roberts
Corporate Officer/Principal at Apitope Technology (Bristol) Ltd.
Network origin in Graham Roberts first degree
Entity | Entity type | Industry | |
---|---|---|---|
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.
11
| Subsidiary | Miscellaneous Commercial Services | 11 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Graham Roberts via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal | |
BTG, Inc.
BTG, Inc. Information Technology ServicesTechnology Services BTG, Inc. provides information systems and technical services to government and commercial enterprises. The company was founded in 1982 and is headquartered in Fairfax, VA. | Information Technology Services | Corporate Officer/Principal | |
Life Sciences, Inc.
Life Sciences, Inc. Medical SpecialtiesHealth Technology Life Sciences, Inc. is a private company that is committed to saving lives and futures by providing superior products and services for scientific research. The company is based in St. Petersburg, FL. The company's offerings include AMV-RT, T7 RNA Polymerase, RNase H, NASBA, Lyophilized Products, and Services. The company was founded by Roderick N. Carter. | Medical Specialties | Director/Board Member | |
FTSE Group
FTSE Group Investment Banks/BrokersFinance FTSE Group creates and manages stock indices. The firm provides indexing and analytic solutions. Its services are offered to pension funds, asset managers, ETF providers and investment banks for investment analysis, performance measurement, asset allocation and hedging. The company was founded by Mark Makepeace in 1995 and is headquartered in London, the United Kingdom. | Investment Banks/Brokers | Corporate Officer/Principal | |
The Medical Research Council
The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member Public Communications Contact Corporate Officer/Principal | |
Janssen-Cilag International NV
Janssen-Cilag International NV BiotechnologyHealth Technology Part of Johnson & Johnson, Janssen-Cilag International NV is a Belgian company that develops novel medicines and solutions. Bart Willem van Zijll Langhout has been the CEO of the company since 2009. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Powderject Pharmaceuticals Plc
Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK | Medical Specialties | Director of Finance/CFO | |
Ernst & Young LLP (Missouri)
Ernst & Young LLP (Missouri) Miscellaneous Commercial ServicesCommercial Services Ernst & Young provides accounting services. Its services include auditing, accounting, tax and transaction services, assurance and advisory business, online transaction advisory and a wide range of financial services. The company was founded by Arthur Young and Alwin C. Ernst in 1881 and is headquartered in Kansas City, MO. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Holzworth Holdings, Inc.
Holzworth Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Holzworth Holdings, Inc. conducts health research and provides technical, professional, and consulting services. The company was founded on December 19, 1996 and is headquartered in Durham, NC. | Miscellaneous Commercial Services | Chief Operating Officer | |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NHS AG
NHS AG Advertising/Marketing ServicesCommercial Services NHS AG is an advertising agency. | Advertising/Marketing Services | Corporate Officer/Principal | |
University of Bristol | College/University | Corporate Officer/Principal | |
Ghent University | College/University | Doctorate Degree | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member | |
Quintiles UK Ltd. | Corporate Officer/Principal | ||
Hasselt University | College/University | Graduate Degree Doctorate Degree | |
Biotechnological Enzymatic Catalyse NV
Biotechnological Enzymatic Catalyse NV Food: Major DiversifiedConsumer Non-Durables Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium. | Food: Major Diversified | Director/Board Member Director/Board Member | |
Université Catholique de Louvain | College/University | Graduate Degree | |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Investment Managers | Founder Private Equity Investor | |
VOLUNTIS S.A. | Packaged Software | Director/Board Member | |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Biotechnology | Director/Board Member Chairman Founder Chairman Chief Executive Officer Director/Board Member Corporate Officer/Principal Chief Operating Officer | |
SEPS Pharma NV
SEPS Pharma NV Pharmaceuticals: GenericHealth Technology SEPS Pharma NV provides controlled drug delivery and develops self emulsifying pro drug systems. Its services include preformulation, formulation development and analytical development. The company was founded on October 19, 2007 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Life Sciences Consultancy | Founder | ||
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Life Sciences Development Campus NV
Life Sciences Development Campus NV Miscellaneous Commercial ServicesCommercial Services Life Sciences Development Campus NV provides research and development services in the field of biomedical life sciences. The company is headquartered in Abis, BelGium. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
V&V Invest BV /BE/
V&V Invest BV /BE/ Real Estate DevelopmentFinance V&V Invest BV is a residential construction company based in Hasselt, Belgium. and has subsidiaries in Belgium. The Belgian company specializes in developing residential construction projects. | Real Estate Development | Director/Board Member | |
Hogeschool-Universiteit Brussel | College/University | Graduate Degree | |
Vesalius Biocapital II Partners SARL | Corporate Officer/Principal Founder | ||
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Solvay Business School of Economics & Management | College/University | Undergraduate Degree | |
Medinvents NV
Medinvents NV Medical SpecialtiesHealth Technology Medinvents NV engages in the manufacture of biopsy surgical instruments. The company was founded on December 28, 1992 and is headquartered in Hasselt, Belgium. | Medical Specialties | Director/Board Member | |
Bio-Sourcing SA
Bio-Sourcing SA BiotechnologyHealth Technology Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member | |
Andaz Partners | Corporate Officer/Principal | ||
Cube Management Co. | Corporate Officer/Principal | ||
ACTICOR BIOTECH SAS | Biotechnology | Director/Board Member | |
Ncardia SA
Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Newton Biocapital Partners SRL
Newton Biocapital Partners SRL Investment ManagersFinance Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre. | Investment Managers | Founder | |
AQ Partners SRL | Corporate Officer/Principal | ||
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder | |
Ncardia Holding SA
Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | Biotechnology | Director/Board Member | |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
A Q Invest SRL | Corporate Officer/Principal |
Statistics
International
Belgium | 27 |
United States | 9 |
United Kingdom | 8 |
Netherlands | 4 |
Luxembourg | 3 |
Sectoral
Health Technology | 21 |
Commercial Services | 9 |
Consumer Services | 7 |
Finance | 6 |
Technology Services | 3 |
Operational
Director/Board Member | 74 |
Corporate Officer/Principal | 29 |
Founder | 10 |
Independent Dir/Board Member | 8 |
Chief Tech/Sci/R&D Officer | 7 |
Most connected contacts
- Stock Market
- Insiders
- Graham Roberts
- Company connections